File(s) not publicly available
Pegfilgrastim in children with severe congenital neutropenia
journal contribution
posted on 2023-06-08, 13:26 authored by Francesca Fioredda, Michaela Calvillo, Marina Lanciotti, Tiziana Lanza, Laura Giunti, Elio Castagnola, Ines Lorenzi, Rossella Tonelli, Pietro Ghezzi, Carlo DufourTwo pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.
History
Publication status
- Published
Journal
Pediatric Blood and CancerISSN
1545-5017Publisher
Wiley-BlackwellExternal DOI
Issue
3Volume
54Page range
465-467Department affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-11-02Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC